China’s C-List in Practice: Early Huiminbao Integration Signals
A practical discussion with Professor Wanyan on Huiminbao benefit design changes, regional adoption differences, local negotiation dynamics, and what early implementation may signal for broader commercial insurance integration.
China’s C-List: Behind-the-Scenes Negotiation Dynamics
A practical implementation deep-dive into China’s 2025 C-List negotiation process with Professor Wanyan — covering insurer participation, NHSA’s role, selection criteria, pricing negotiation, and future commercial insurance formulary trends.
China’s 2026 Dual-List Draft Workplan: Earlier Innovation Access, Tighter Lifecycle Pricing Discipline
China’s 2026 NRDL draft workplan signals a more integrated, lifecycle-oriented reimbursement framework: earlier access for innovative therapies, closer regulatory–reimbursement alignment anchored in RWE, and tighter pricing discipline for mature and me-too products.
RWE and the Quiet Rewiring of China’s Reimbursement System
Five recent policy releases show how real-world evidence is quietly reshaping pricing, reimbursement, and clinical adoption for both innovative and established medicines in China.
Three Shifts Reshaping China’s Drug Payment System: Implications for Global Pharma
China’s drug payment system is shifting from isolated policy levers toward an environment defined by their interaction. Recent signals are beginning to link pricing, launch timing, and multi-payer access in ways that materially change how global pharma approaches China.
China Establishes Market-Price Database, Reshaping Global Pricing Signals
China’s new drug price database marks a subtle but important shift in price governance—separating how market prices are recorded from how reimbursement is negotiated. The change reshapes pricing signals in ways that matter for both domestic innovators and multinational firms.
China’s Biosimilar VBP: Emerging Rules, Pricing Dynamics, and What Early Signals Suggest
China’s VBP is shifting toward biosimilars, raising strategic questions for global manufacturers: Will the country cultivate an EU-style biosimilar market—and will VBP mirror generics or follow a modified path? This series interprets early policy signals to help companies prepare.
NHSA Moves Forward with China’s First Dual-List Adjustment for NRDL and Commercial Drug Catalog
What will China’s new dual-list mechanism mean for launch timing, pricing risks, and long-term market potential for innovative drugs?
NHSA Consults on 2025 Dual-List Adjustment Work Plan for NRDL and Commercial Drug List
The Dual-List Adjustment Mechanism marks a pivotal shift in China’s reimbursement system, prompting key strategic questions for innovative drug makers.
The Future of Innovative Medicine Pricing and Reimbursement in China: Signals from the 2024 NRDL Negotiations
These developments call for a global pricing strategy rooted in China's evolving reimbursement infrastructure, breaking siloed thinking to balance short-term goals with long-term growth.
